✦ LIBER ✦

Aromatase inhibitors for early breast cancer therapy: A choice of effective treatment strategies

✍ Scribed by J.M. Dixon; N. Bundred

Book ID: 116442558
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 68 KB
Volume: 32
Category: Article
ISSN: 0748-7983
DOI: 10.1016/j.ejso.2005.09.015

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Aromatase inhibitors for therapy of adva

Aromatase inhibitors for therapy of advanced breast cancer

✍ James N. Ingle; Vera J. Suman 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 140 KB

The use of aromatase inhibitors in adjuv

The use of aromatase inhibitors in adjuvant therapy for early breast cancer

✍ Walter Jonat; Felix Hilpert; Nicolai Maass 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 250 KB

Aromatase inhibitor development for trea

Aromatase inhibitor development for treatment of breast cancer

✍ Shigeru Masamura; Herman Adlercreutz; Harold Harvey; Allan Lipton; Laurence M. D 📂 Article 📅 1995 🏛 Springer US 🌐 English ⚖ 649 KB

Clinical strategies for rationale combin

Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer

✍ Stephen R.D. Johnston; Lesley-Ann Martin; Alex Leary; Julia Head; Mitch Dowsett 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 293 KB

Aromatase inhibitor therapy: toxicities

Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer

✍ Susan F. Dent; Rania Gaspo; Michelle Kissner; Kathleen I. Pritchard 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 537 KB

Adjuvant aromatase inhibitor therapy for

Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data

✍ G. Grana 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB

## Abstract Tamoxifen is the established adjuvant treatment for postmenopausal women with hormone‐sensitive early breast cancer. However, the side‐effects associated with tamoxifen therapy have prompted a search for safer and potentially more effective endocrine agents. Results from randomized tria